Roche Gears Up For Potential Neuroscience Breakthroughs
Huntington’s Drug Could Get Nod in 2020
Neuroscience could be this decade’s big growth story, but clinical and market access challenges differ to oncology.
You may also be interested in...
Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.
Vydaqel saw its uptake take off in the US last year. UK’s NICE to pass judgement on cost effectiveness by June.
CAR-T therapies are groundbreaking in clinical terms, but have hit barriers in uptake. Can BMS’s challenger go one better than Yescarta and Kymriah?